Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Validity of Free Testosterone and Free Estradiol Determinations in Serum Samples from Postmenopausal Women by Theoretical Calculations

Sabina Rinaldi, Annabelle Geay, Henri Déchaud, Carine Biessy, Anne Zeleniuch-Jacquotte, Arslan Akhmedkhanov, Roy E. Shore, Elio Riboli, Paolo Toniolo and Rudolf Kaaks
Sabina Rinaldi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annabelle Geay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henri Déchaud
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carine Biessy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Zeleniuch-Jacquotte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arslan Akhmedkhanov
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roy E. Shore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elio Riboli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Toniolo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rudolf Kaaks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published October 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In this study, we validated measurements of free testosterone (fT) and free estradiol (fE2) concentrations calculated from total serum concentrations of testosterone (T), estradiol (E2), and sex hormone-binding globulin (SHBG), measured by direct, commercial radioimmunoassays, by comparison with reference measurements obtained by dialysis plus an in-house radioimmunoassay after extraction and chromatographic purification. The study was conducted in serum samples from 19 postmenopausal women who were part of an ongoing prospective cohort study. We also performed sensitivity analyses to examine the robustness of the theoretical calculations. Sensitivity analyses showed that in this population, competitive binding of dihydrotestosterone and total T could be ignored in the calculation of fE2, and competitive binding by dihydrotestosterone does not need to be taken into account for calculation of fT. Furthermore, variations in albumin and SHBG concentrations had negligible effects on fT and fE2 calculations. Values of fT and fE2, calculated from total T and E2 concentrations obtained by the same in-house radioimmunoassay used for the dialysis method, correlated highly with the measurements by dialysis (Pearson’s coefficients of correlation above 0.97). When calculating fT and fE2 using total T and total E2 concentrations obtained by different direct radioimmunoassays, almost all kits gave good correlations with the reference method for fT (Pearson’s r > 0.83), but only a few gave good correlations for fE2 (Diagnostic System Laboratories and DiaSorin; r > 0.80). The direct radioimmunoassays giving the best correlation for fT and fE2 with the dialysis method were those that best measured total concentrations of T and E2. Furthermore, mean values of fT and fE2 corresponded well to mean values by the reference method if SHBG measurements were also well calibrated. We conclude that in postmenopausal women, theoretical calculations are valid for the determination of fT and fE2 concentrations and can give reliable estimation of cancer risk in epidemiological studies when the total concentrations of T, E2, and SHBG are measured accurately.

Introduction

Epidemiological studies have shown relationships of breast and endometrial cancers with concentrations of T2 and E2 in blood among postmenopausal women (1, 2, 3) . Both T and E2 are transported in blood bound to proteins (4 , 5) , of which the most important are albumin and SHBG. Together, these proteins bind >97% of T and E2 circulating in blood (6) . The percentage of T and E2 that circulates either free (i.e., unbound to any protein) or bound to albumin is defined as the “bioavailable fraction” because only this fraction can potentially cross cellular membranes and bind to the nuclear steroid receptors (7) . The bioavailable fraction is virtually equal to the fraction not linked to SHBG (8) and represents >50% of total E2 and >30% of total T in normal women and men (9) . fT and fE2 are most directly available to tissues under physiological conditions and generally correlate strongly with concentrations of T and E2 unbound to SHBG (8) .

To clarify the roles of fT and fE2 (and therefore of their bioavailable fractions) in the development of cancer in postmenopausal women, it is important to have precise and inexpensive methods for their measurement that can be easily applied to large-scale epidemiological studies. Several methods have been set up for the measurement of fT and fE2 rather than for the measurement of the bioavailable fractions because in normal subjects, the free and bioavailable fractions are very highly correlated (8) , and the methods for the measurement of the T and E2 bioavailable fractions require a large amount of biological sample (10, 11, 12) . The most common methods for measurement of fT and fE2 are based on dialysis (13 , 14) , ultrafiltration (15, 16, 17, 18) , and gel filtration (19 , 20) . These methods do not measure the absolute concentrations of fT and fE2 directly but measure fT and fE2 as percentages of the total circulating T and E2 concentrations. Absolute levels of fT and fE2 are then determined by multiplying the percentage of fT or fE2 with measurements of total T and E2, respectively (13) . Gel filtration has been largely abandoned nowadays because it may change thermodynamic equilibrium conditions during the assay, and because it may strip hormones from binding proteins (21) . Dialysis is considered as the reference method for the measurement of fT and fE2, but it is slow to perform, technically demanding, laborious and expensive, and requires a relatively large sample volume. Ultrafiltration assays are faster, but they remain technically demanding and cumbersome.

An alternative and simple method is to use theoretical calculations of fT and fE2 from total plasma concentrations of T, E2, and SHBG. The free androgen index, calculated as the quotient 100 × T/SHBG (where T = total molar concentration of T, and SHBG = total molar concentration of SHBG in plasma), has been found to be inaccurate as an index of calculation of fT concentration in men, postmenopausal women, and hyperthyroid subjects (22) . However, the validity of more complex theoretical calculations, using mass action models based on concentrations of total hormones in blood and their affinity constants for albumin and SHBG (6 , 9 , 23 , 24) , has not been extensively examined.

In this paper, we present the results of a study in which we tested the validity of different theoretical calculations for fT and fE2 in postmenopausal women by comparison with reference values obtained by equilibrium dialysis plus an in-house radioimmunoassay after chromatographic purification. Values of total T and E2 for fT and fE2 calculations were obtained by direct, commercially available radioimmunoassays and by an in-house indirect radioimmunoassay. Furthermore, to test the robustness of the theoretical calculations, we simulated the effects on calculated values of fT and fE2 that may be induced by changes in steroid hormone concentrations and levels of SHBG and albumin (sensitivity analyses).

Materials and Methods

Subjects and Blood Collection.

Serum samples were taken from 20 postmenopausal women who participated in the New York University Women’s Health Study, an ongoing prospective cohort study in New York. The 20 study subjects were selected at random from a subset of about 2000 women who had donated blood at least four times during the course of the study. For these women, a pooled serum sample of about 24 ml was made from serum samples obtained on two different occasions, which was then re-aliquoted into 1-ml vials and frozen until the measurement of hormones by radioimmunoassays and dialysis.

For one subject, SHBG concentration was very high [213 nmol/liter, a concentration well above the maximum physiological value considered normal in women (between 17 and 87 nmol/liter, a range established on SHBG measurements by the same radioimmunoassay used in this study on more than 1500 postmenopausal women at the Laboratory for Hormone Assays, Unit of Nutrition and Cancer, IARC, Lyon, France)]. This subject was therefore excluded from the study, following the principle that this type of subject would also have been excluded from an epidemiological study, and 19 subjects thus remained for our final analyses.

Measurements of Total T, Total E2, and SHBG Concentrations.

Concentrations of total T and total E2 were measured as described in detail previously (25) . In brief, total T and total E2 were measured by an in-house radioimmunoassay after extraction by diethyl ether and chromatographic purification on celite columns (celite method), as well as by commercially available direct radioimmunoassays. For total T, direct radioimmunoassays were obtained from Immunotech (Marseille, France), Orion (Orion Diagnostica, Espoo, Finland), Cis-Bio International (Gif-sur-Yvette, France), Diagnostic System Laboratories (Webster, TX), DiaSorin (Saluggia, Italy), and Byk-Sangtec Diagnostica (Dietzenbach, Germany); for total E2, direct radioimmunoassays were obtained from Immunotech, Cis-Bio International, DSL, DiaSorin, and Bio Source Europe (Nivelles, Belgium).

For SHBG, concentrations were measured by two solid-phase sandwich immunoradiometric assays (Cis-Bio International and DSL). The immunoradiometric assay by Cis-Bio International had been validated previously in our laboratories against a reference method based on total T binding capacity (9 , 26) . The values of SHBG used for the theoretical calculations and for the sensitivity analyses were those obtained by the Cis-Bio International immunoassay.

Measurements by the celite method were done at the Central Laboratory for Biochemistry, Hôpital Neuro-cardiologique (Lyon, France), whereas the direct assays were all performed at the Laboratory for Hormone Assays, Unit of Nutrition and Cancer (IARC).

Measurements of fT and fE2 by Equilibrium Dialysis.

Measurements of fT and fE2 by equilibrium dialysis were done as described in detail previously (13) . In brief, dialysis was performed at 37°C using dialysis membranes (Union Carbide, Chicago, IL) for the separation of free and bound fractions of hormones. For each subject, 1 ml of 1:5-diluted serum sample was put into the dialysis membrane, and a known amount of tritiated T or E2 ([3H]T or [3H]E2, about 10,000 cpm in 3 ml of phosphate buffer) was added. After dialysis, 650 μl of the solution inside the dialysis casing and 1 ml of the saline outside the casing were extracted with ethyl ether, and the organic fraction was dried under a gentle stream of nitrogen. The dried extracts were redissolved in 750 μl of saline. Five hundred μl of the solution were then added to 3 ml of scintillation liquid, and [3H]T or [3H]E2 activities were counted in a liquid scintillation counter with automatic quench correction. The percentage of the free fraction was then calculated as follows: Math where D is the total concentration of free steroid in volume Vd outside the casing, and R is the total concentration of steroid in volume Vf inside the casing (13) .

To calculate the absolute concentrations of fT or fE2, the percentage free obtained by dialysis was multiplied by the total concentration of T or E2, respectively. Total T and total E2 were measured by radioimmunoassay after organic extraction and chromatographic prepurification on celite columns (celite method), as described in detail previously (25) .

All of the measurements by dialysis plus the celite method were performed at the Central Laboratory for Biochemistry, Service de Radio analyse et Radiopharmacie, Hôpital Neuro-cardiologique.

Calculations of fT and fE2 Using Mass Action Equations.

Two different sets of equations based on the mass action law were used for the calculation of fT and fE2.

The first set, previously discussed by Vermeulen et al. (23) for fT, relies on the assumption that the concentration of fT (or fE2) in blood is determined mainly by the interaction between SHBG and albumin, and total T (or total E2) through the different affinity constants of the peptides for these steroid hormones, and that other hormones present in blood do not influence this equilibrium much; that is: Math where [T] and [E2] are total T and total E2 concentrations, respectively; [fT] and [fE2] are fT and fE2 concentrations; KsT and KsE2 are the affinity constants of SHBG for T and E2; N1 = KaT Ca+ 1, and N2 = KaE2 Ca+ 1, where Ca is the albumin concentration (considered as equal to 43 g/liter − 6.5 10−4 mol/liter), and KaT and KaE2 are the affinity constants of albumin for T and E2.

The second set of equations, discussed by Södergard et al. (6) , is based on the assumption that different hormones present in blood compete for the same protein binding sites, which may have different affinity constants for each of these hormones, and that all of the binding sites of each protein are equivalent and independent.

In our study, we considered only the interactions among T, E2, and DHT because in postmenopausal women, these are the most important steroids by their relative concentrations and affinity for the binding proteins. It has been demonstrated earlier that other metabolites (e.g., 5-androstene-3β,17β-diol and androstane-3α,17β-diol) influenced fT and fE2 concentrations only very slightly (23) . Therefore, the system of equations that we considered for the calculations of fT, fDHT, and fE2 was the following: Math where [E2], [T], and [DHT] are total concentrations of E2, T, and DHT, respectively; [fE2], [fT], and [fDHT] are concentrations of fE2, T, and DHT, respectively; [Ca] is the concentration of albumin; [CSHBG] is the concentration of SHBG; KaE2, KaT, and KaDHT are the affinity constants of albumin for E2, T, and DHT; and KsE2, KsT, and KsDHT are the affinity constants of SHBG for E2, T, and DHT. This is a system of three nonlinear equations with three unknown variables (fE2, fT, and fDHT). The values of the affinity constants used in this study were the following: KsT = 1 × 109 liters/mol, KaT = 4.06 × 104 liters/mol, KsE2 = 3.14 × 108 liters/mol, KaE2 = 4.21 × 104 liters/mol, KsDHT = 3 × 109 liters/mol, and KaDHT = 3.5 × 104 liters/mol.

We used Maple software version 6 (Waterloo Maple Inc., Waterloo, Canada) to solve this system of equations and to find values for the three unknown variables (fT, fE2, and fDHT).

Sensitivity Analyses of Mass Action Equations.

Sensitivity analyses on the theoretical calculations consisted of simulating the effects of changes in the total concentrations of E2, T, DHT, albumin, and SHBG on (calculated) concentrations of fT and fE2. Effects were evaluated mainly by comparison of mean measurement values and by the calculation of Pearson’s coefficients of correlation between calculated values before and after changes in total hormone values.

Comparison of Theoretical Calculations with Equilibrium Dialysis Method.

To validate Eq. A and Eq. B for the calculations of fT and fE2, the values of fT and fE2 obtained by these equations for the 19 study subjects were compared with the values obtained by equilibrium dialysis. All analyses were performed on log10-transformed variables to approximately normalize their frequency distributions. Statistical analyses included the calculation of geometric means and CIs and Pearson’s correlation coefficients.

Results

Sensitivity Analyses

Influence of Competing Steroids and Albumin Levels on Calculated fT and fE2 Concentrations.

Variations (in the postmenopausal range) of the concentrations of DHT and E2 had negligible effects on the measurements of fT by Eq. B , leading to a maximum change in mean fT concentrations of only 0.68% compared with the values obtained when using total T concentrations by the celite method. The same effect was observed on calculated fE2 when varying DHT and T concentrations in the postmenopausal range (maximum change of 0.45%). Furthermore, the relative ranking of the 19 subjects by calculated values of fT and fE2 also remained virtually unaffected by these variations in total hormone concentrations (Pearson’s correlations > 0.996). FT and fE2 could therefore be calculated by the simpler Eq. A with virtually identical results.

The variation in the absolute levels of albumin between 30 and 60 mg/ml for all of the subjects led to a maximum change of 12% in mean fT concentrations and a 22% variation in mean fE2 levels. Pearson’s coefficients of correlation with the reference values obtained by dialysis plus celite method were always >0.97. In addition, the attribution of random albumin values between 40 and 50 g/liter to the 19 subjects had very little effect on the relative classification of these women by relative calculated fT and fE2 values (Pearson’s correlations of 0.97 and higher between fT and fE2 values obtained Eq. A and reference values obtained by dialysis plus celite method). Thus, changes in absolute levels of albumin concentration affected absolute levels of calculated fT and fE2 but appeared to have very little effect on the relative classification of subjects from low to high values.

Influence of Different SHBG Measurements on Calculated fT and fE2 Concentrations.

Mean SHBG values were 52.68 and 134.58 nmol/liter for the Cis-Bio International and DSL assays, respectively, and Pearson’s coefficient of correlation between the two SHBG assays was 0.96. Using total T and total E2 concentrations from the celite method, the mean values of fT and fE2 calculated by Eq. A were 2.91 and 0.12 pmol/liter, respectively, when SHBG was measured by the DSL assay, instead of 4.70 and 0.16 when the SHBG assay of Cis-Bio International was used. However, correlations were above 0.995 for fT and fE2 calculated from the two series of SHBG values.

To simulate the effects on fT and fE2 concentrations when SHBG values do not correlate with the individual’s true levels, concentrations obtained by the Cis-Bio International assay were randomized among the 19 subjects of the study (randomizations and calculations were repeated 100 times). On average, randomized concentrations of SHBG had close-to-zero Pearson’s coefficients of correlation with the individual’s original (“true”) SHBG values (mean r = −0.06). Nevertheless, calculated values of fE2 remained highly correlated with those calculated with the correct SHBG values (mean value of 0.94), as well as with fE2 values from the dialysis method (mean value of 0.96). However, the correlations for calculated values of fT dropped with respect to those where correct SHBG values were used (mean r = 0.78) or with respect to the values by dialysis plus celite method (r = 0.75).

Comparison between Calculated Values for fT and fE2 and Reference Values by Dialysis.

Geometric means and 95% CIs for fT and fE2 obtained by the different methods are shown in Table 1⇓ . The SHBG values used in the calculations were those obtained by the Cis-Bio International assay (the Cis-Bio International assay was found to have mean values closest to a reference assay based on steroid-binding capacity3 ). Concentrations of fT and fE2 calculated by Eq. A were only slightly higher than those obtained by dialysis plus celite method (10% for fT and 19% for fE2), when also total T and total E2 concentrations were measured by the celite method, and when SHBG was measured by the Cis-Bio International kit. However, values of fT and fE2 calculated from T and E2 concentrations by different direct radioimmunoassays were systematically higher than the reference measurements by the dialysis plus celite method. These large variations in mean fT and fE2 values paralleled equally large variations in mean levels of the absolute concentrations of T and E2 by the different immunoassay kits [see detailed results in our previous report (25)] .

View this table:
  • View inline
  • View popup
Table 1

Means and CIs (pmol/liter) of T, fT, E2, and fE2 obtained by dialysis and by theoretical calculations from total T and E2 concentrationsa

Pearson’s coefficients of correlation between the different methods for measurement or calculation of fT and fE2 are in Table 2⇓ . For both fT and fE2, the highest correlations (r > 0.97) between values calculated by Eq. B and dialysis were found when fT and fE2 were calculated from total T and E2 measured by the celite method using the SHBG kit by Cis-Bio International (Fig. 1, a and b⇓ , respectively). However, good correlations with the reference method (r > 0.85) were also found when fT was calculated from total T concentrations by the direct assay (Immunotech) that gave the highest correlation with total T measured by celite method [r = 0.86; see our previous report (25)] . A very similar observation was made for fE2 (Table 2)⇓ . Assays that correlated best for total E2 measurements with the celite method (DiaSorin and DSL, r > 0.84) gave good correlations for fE2 compared with the dialysis plus celite method (r > 0.80). Conversely, direct assays of total E2 that correlated poorly with measurements by the celite method (Immunotech; r = 0.29) also resulted in poor correlation (r = 0.39) for calculated fE2 with fE2 measured by the dialysis plus celite method.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

a and b, relationships between fT and fE2 (pmol/liter) measured by dialysis and as calculated from SHBG, total T, and total E2 (total T and E2 measured by the celite method).

View this table:
  • View inline
  • View popup
Table 2

Pearson’s coefficients of correlation and CIs between fT and fE2 measurements by dialysis plus the celite method and by theoretical calculations (by Eq. A )a

Discussion

We examined the validity of calculated concentrations of fT and fE2 in serum samples from postmenopausal women by sensitivity analyses (theoretical simulations) as well as by comparison with measurements obtained by the equilibrium dialysis and celite method.

Our simulations with Eq. B showed that influences (due to competitive binding) of T and DHT on the calculation fE2 and influences of DHT and E2 on the calculation of fT could be ignored, at least for this random sample of postmenopausal women, and that virtually identical values of fT and fE2 are obtained by the much simpler Eq. A . This result is most likely explained by the fact that, especially in postmenopausal women with normal (i.e., nonpathologic) levels of endogenous steroids and SHBG, SHBG is present in large excess compared with T and E2. Thus, there is only limited competition for the binding sites on this protein. Vermeulen et al. (23) made similar observations, even for men and premenopausal women (who have higher concentrations of T and E2, respectively, than postmenopausal women), and also proposed the reduced Eq. A for the calculation of fT levels for these population groups. A much simpler equation has the advantages of requiring less data (i.e., no need to measure DHT or additional steroids) and of being solvable by the most common computer programs used for statistical analyses in epidemiological studies (SAS; SAS Institute, Cary, NC).

To validate the measures of fT and fE2 obtained by theoretical calculations from different measurements of total T, E2, and SHBG (by direct immunoassays), we compared them with reference measurements obtained by equilibrium dialysis (to determine the ratio of free:total concentrations of T or E2) multiplied by a reference measure of total T or E2 obtained by indirect immunoassay after organic extraction and purification on celite columns. The use of the celite method as a reference for validation of direct assays of total T and E2 by commercially available kits has been described in detail previously (25) . The concentrations of fT and fE2 in serum samples from postmenopausal women obtained by dialysis plus the celite method were comparable with those published in the literature (23 , 27, 28, 29, 30, 31) . Comparisons with these reference measurements showed very good validity of calculated values for fT and fE2 whenever measurements of total plasma T and E2 corresponded well to the values of the celite method. Furthermore, in situations where mean levels of direct assays of total T or E2 were substantially higher than mean celite values, but where those assays correlated strongly with values from the celite method, calculated fT and fE2 values also remained highly correlated with the reference values based on equilibrium dialysis plus celite method but then had higher mean concentrations of fT or fE2 as well.

Additional analyses showed that whereas SHBG levels are the major determinant of fT or fE2 levels measured as a percentage of total T and E2, absolute concentrations of fT and fE2 depended more predominantly on concentrations of total T and E2. Measurements of total T, obtained by the celite method or by the different direct radioimmunoassays, showed relatively strong correlations with fT values that were calculated or measured by dialysis (Pearson’s correlations between 0.88 and 0.97). By contrast, the percentage of fT did not show any clear correlation with levels of total T (Pearson’s correlations varied between −0.23 and 0.39, depending on the combination of assays for T and SHBG from which fT was calculated) but correlated strongly and inversely with SHBG measurements (r = −0.94 for SHBG by Cis-Bio International assay). Similar results were obtained for fE2, which correlated directly with total E2 concentrations measured by the celite method or by the different direct immunoassays (Pearson’s correlations between 0.86 and 0.996), whereas fE2 as a percentage of total E2 correlated strongly and inversely with SHBG values (r = −0.95 for SHBG by Cis-Bio International assay) but very poorly with total E2 (correlations between 0.11 and 0.36).

Globally, these results indicate that, at least within a random sample of postmenopausal women with SHBG levels within the normal physiological range, variations in levels of albumin and SHBG did not have much influence on the relative ranking of subjects. This limited influence of SHBG and albumin levels was confirmed by our theoretical simulations, which showed that between-subject variations in albumin level, within the normal range of about 40–50 g/liter, had very little influence on the relative classification of subjects by calculated levels of fT and fE2 and that even changes in albumin concentrations over a broader range (30–60 g/liter) had only modest effects on calculated concentrations of fT and fE2. Likewise, between-subject variation in SHBG levels (e.g., randomization of SHBG values of the 19 subjects retained for this study) had only moderate effects on the subjects’ classification by relative fT and fE2 levels. However, our data also showed that correct calibration of the scale of SHBG measurements remains a requirement, if the objective is to obtain accurate mean calculated values of fT and fE2 (this was illustrated by the difference in mean values for fT and fE2 calculated from SHBG measurements from the Cis-Bio International or DSL kits).

Although variations in SHBG level had only a modest impact on calculated values of fT and fE2 in our population sample of normal postmenopausal women, this may not be true for other populations that include subjects with extreme values of SHBG (as in many clinical situations). Indeed, when we considered a population of 90 premenopausal women including cases with both pathologically low and high levels of SHBG (from 5 to 272 nmol/liter) and T (from 5.1 to 104 ng/100 ml), randomization of SHBG levels among the subjects strongly affected the relative ranking of subjects by calculated concentrations of fT (average Pearson’s coefficient of correlation of 0.30 with fT values calculated from the correct SHBG concentrations).

In conclusion, theoretical calculations can provide an accurate method for the determination of fE2 and fT in serum samples from postmenopausal women, provided that the concentrations of total T, total E2, and SHBG are measured accurately. Direct radioimmunoassays are methods that best meet the needs of epidemiological studies in terms of speed, cost, and sample volume required. Our study shows that direct assay kits for the measurement of total T and E2 can be found that allow at least an accurate classification of postmenopausal women by their relative levels of fT and fE2, although the exact scaling of measurements, especially for fE2, may remain problematic.

Acknowledgments

We thank Francine Claustrat and Veronique Morin-Raverot for assistance with dialysis and celite method measurements, David Achaintre and Béatrice Vozar for technical support with the direct radioimmunoassays, and Jennie Dehedin and Odile Drutel for secretarial help.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 To whom requests for reprints should be addressed, at IARC, Unit of Nutrition and Cancer, 150 Cours Albert Thomas, 69372 Lyon, France. Fax: 33-04-72-73-85-75.

  • ↵2 The abbreviations used are: T, testosterone; fT, free testosterone; E2, estradiol; fE2, free estradiol; SHBG, sex hormone-binding globulin; DHT, dihydrotestosterone; fDHT, free dihydrotestosterone; CI, confidence interval.

  • ↵3 H. Déchaud, unpublished results.

  • Received February 4, 2002.
  • Revision received May 17, 2002.
  • Accepted May 29, 2002.

References

  1. ↵
    Thomas H. V., Reeves G. K., Key T. J. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control, 8: 922-928, 1997.
    OpenUrlCrossRefPubMed
  2. ↵
    Akhmedkhanov A., Zeleniuch-Jacquotte A., Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann. N. Y. Acad. Sci., 943: 296-315, 2001.
    OpenUrlPubMed
  3. ↵
    Potischman N., Hoover R. N., Brinton L. A., Siiteri P., Dorgan J. F., Swanson C. A., Berman M. L., Mortel R., Twiggs L. B., Barrett R. J., Wilbanks G. D., Persky V., Lurain J. R. Case-control study of endogenous steroid hormones and endometrial cancer. J. Natl. Cancer Inst. (Bethesda), 88: 1127-1135, 1996.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Anderson D. C. Sex-hormone-binding globulin. Clin. Endocrinol. (Oxf.), 3: 69-96, 1974.
    OpenUrlCrossRefPubMed
  5. ↵
    Pardridge W. M. Plasma protein-mediated transport of steroid and thyroid hormones. Am. J. Physiol., 252: E157-E164, 1987.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Sodergard R., Backstrom T., Shanbhag V., Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J. Steroid Biochem., 16: 801-810, 1982.
    OpenUrlCrossRefPubMed
  7. ↵
    Bernstein L., Ross R. K. Endogenous hormones and breast cancer risk. Epidemiol. Rev., 15: 48-65, 1993.
    OpenUrlFREE Full Text
  8. ↵
    Pardridge W. M. Serum bioavailability of sex steroid hormones. Clin. Endocrinol. Metab., 15: 259-278, 1986.
    OpenUrlCrossRefPubMed
  9. ↵
    Dunn J. F., Nisula B. C., Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab., 53: 58-68, 1981.
    OpenUrlCrossRefPubMed
  10. ↵
    Dechaud H., Lejeune H., Garoscio-Cholet M., Mallein R., Pugeat M. Radioimmunoassay of testosterone not bound to sex-steroid-binding protein in plasma. Clin. Chem., 35: 1609-1614, 1989.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Tremblay R. R., Dube J. Y. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception, 10: 599-605, 1974.
    OpenUrlCrossRefPubMed
  12. ↵
    Loric S., Guechot J., Duron F., Aubert P., Giboudeau J. Determination of testosterone in serum not bound by sex-hormone-binding globulin: diagnostic value in hirsute women. Clin. Chem., 34: 1826-1829, 1988.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Slaunwhite R. W. The binding of estrogens, androgens and progesterone by plasma protein in vitro. Steroids, : 478-494, 1960.
  14. ↵
    Cooke R. R., McIntosh J. E., McIntosh R. P. Circadian variation in serum free and non-SHBG-bound testosterone in normal men: measurements, and simulation using a mass action model. Clin. Endocrinol. (Oxf.), 39: 163-171, 1993.
    OpenUrlPubMed
  15. ↵
    Vlahos I., MacMahon W., Sgoutas D., Bowers W., Thompson J., Trawick W. An improved ultrafiltration method for determining free testosterone in serum. Clin. Chem., 28: 2286-2291, 1982.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Adachi K., Yasuda K., Fuwa Y., Goshima E., Yamakita N., Miura K. Measurement of plasma free steroids by direct radioimmunoassay of ultrafiltrate in association with the monitoring of free components with [14C]glucose. Clin. Chim. Acta, 200: 13-22, 1991.
    OpenUrlCrossRefPubMed
  17. ↵
    Dowsett M., Mansfield M. D., Griggs D. J., Jeffcoate S. L. Validation and use of centrifugal ultrafiltration-dialysis in the measurement of percent free oestradiol in serum. J. Steroid Biochem., 21: 343-345, 1984.
    OpenUrlCrossRefPubMed
  18. ↵
    Green P. J., Yucis M. J. Free-testosterone determination by ultrafiltration, and comparison with dialysis. Clin. Chem., 28: 1237-1238, 1982.
    OpenUrlFREE Full Text
  19. ↵
    Wheeler M. J., Nanjee M. N. A steady-state gel filtration method on micro-columns for the measurement of percentage free testosterone in serum. Ann. Clin. Biochem., 22: 185-189, 1985.
  20. ↵
    Greenstein B. D., Puig-Duran E., Franklin M. Accurate, rapid measurement of the fraction of unbound estradiol and progesterone in small volumes of undiluted serum at 37°C by miniature steady-state gel filtration. Steroids, 30: 331-341, 1977.
    OpenUrlCrossRefPubMed
  21. ↵
    Csako G. Free hormone measurements. Immunoassay, 423-481, Academic Press 1996.
  22. ↵
    Vermeulen A., Stoica T., Verdonck L. The apparent free testosterone concentration, an index of androgenicity. J. Clin. Endocrinol. Metab., 33: 759-767, 1971.
    OpenUrlCrossRefPubMed
  23. ↵
    Vermeulen A., Verdonck L., Kaufman J. M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab., 84: 3666-3672, 1999.
    OpenUrlCrossRefPubMed
  24. ↵
    Pearlman W. H., Crepy O. Steroid-protein interaction with particular reference to testosterone binding by human serum. J. Biol. Chem., 242: 182-189, 1967.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Rinaldi S., Dechaud H., Biessy C., Morin-Raverot V., Toniolo P., Zeleniuch-Jacquotte A., Akhmedkhanov A., Shore R. E., Secreto G., Ciampi A., Riboli E., Kaaks R. Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol. Biomark. Prev., 10: 757-765, 2001.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Pugeat M., Garrel D., Estour B., Lejeune H., Kurzer M. S., Tourniaire J., Forest M. G. Sex steroid-binding protein in nonendocrine diseases. Ann. N. Y. Acad. Sci., 538: 235-247, 1988.
    OpenUrlCrossRefPubMed
  27. ↵
    Toniolo P. G., Levitz M., Zeleniuch-Jacquotte A., Banerjee S., Koenig K. L., Shore R. E., Strax P., Pasternack B. S. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J. Natl. Cancer Inst. (Bethesda), 87: 190-197, 1995.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Hankinson S. E., Willett W. C., Manson J. E., Colditz G. A., Hunter D. J., Spiegelman D., Barbieri R. L., Speizer F. E. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. (Bethesda), 90: 1292-1299, 1998.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Cauley J. A., Lucas F. L., Kuller L. H., Stone K., Browner W., Cummings S. R. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med., 130: 270-277, 1999.
  30. ↵
    Longcope C., Hui S. L., Johnston C. C., Jr. Free estradiol, free testosterone, and sex hormone-binding globulin in perimenopausal women. J. Clin. Endocrinol. Metab., 64: 513-518, 1987.
    OpenUrlCrossRefPubMed
  31. ↵
    Berrino F., Muti P., Micheli A., Bolelli G., Krogh V., Sciajno R., Pisani P., Panico S., Secreto G. Serum sex hormone levels after menopause and subsequent breast cancer. J. Natl. Cancer Inst. (Bethesda), 88: 291-296, 1996.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
October 2002
Volume 11, Issue 10
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Validity of Free Testosterone and Free Estradiol Determinations in Serum Samples from Postmenopausal Women by Theoretical Calculations
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Validity of Free Testosterone and Free Estradiol Determinations in Serum Samples from Postmenopausal Women by Theoretical Calculations
Sabina Rinaldi, Annabelle Geay, Henri Déchaud, Carine Biessy, Anne Zeleniuch-Jacquotte, Arslan Akhmedkhanov, Roy E. Shore, Elio Riboli, Paolo Toniolo and Rudolf Kaaks
Cancer Epidemiol Biomarkers Prev October 1 2002 (11) (10) 1065-1071;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Validity of Free Testosterone and Free Estradiol Determinations in Serum Samples from Postmenopausal Women by Theoretical Calculations
Sabina Rinaldi, Annabelle Geay, Henri Déchaud, Carine Biessy, Anne Zeleniuch-Jacquotte, Arslan Akhmedkhanov, Roy E. Shore, Elio Riboli, Paolo Toniolo and Rudolf Kaaks
Cancer Epidemiol Biomarkers Prev October 1 2002 (11) (10) 1065-1071;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Early-Life Risk Factors for Breast Cancer
  • Sugary Drink Consumption and Colorectal Cancer Risk
  • HPV Testing in Self-samples and Urine
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement